Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Anthony Hazelton"'
Autor:
Mairead K. Heavey, Anthony Hazelton, Yuyan Wang, Mitzy Garner, Aaron C. Anselmo, Janelle C. Arthur, Juliane Nguyen
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract Probiotic and engineered microbe-based therapeutics are an emerging class of pharmaceutical agents. They represent a promising strategy for treating various chronic and inflammatory conditions by interacting with the host immune system and/o
Externí odkaz:
https://doaj.org/article/509a56f0d80b49ffa33c062d873b4a59
Autor:
Timothy Samec, Kharimat Lora Alatise, Jessica Boulos, Serena Gilmore, Anthony Hazelton, Carleigh Coffin, Angela Alexander-Bryant
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 30, Iss , Pp 95-111 (2022)
Ovarian cancer has shown little improvement in survival among advanced-stage patients over the past decade. Current treatment strategies have been largely unsuccessful in treating advanced disease, with many patients experiencing systemic toxicity an
Externí odkaz:
https://doaj.org/article/6a4af8abcae046f6ba6452cffbc2e0ab
Publikováno v:
Materials Today Bio, Vol 14, Iss , Pp 100248- (2022)
Current delivery strategies for cancer therapeutics commonly cause significant systemic side effects due to required high doses of therapeutic, inefficient cellular uptake of drug, and poor cell selectivity. Peptide-based delivery systems have shown
Externí odkaz:
https://doaj.org/article/6a31904a838842e6914e9ebd2677ce18
Publikováno v:
Materials today. Bio. 14
Current delivery strategies for cancer therapeutics commonly cause significant systemic side effects due to required high doses of therapeutic, inefficient cellular uptake of drug, and poor cell selectivity. Peptide-based delivery systems have shown
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6abaa579a7c3a35dd291cc77313d5b1
https://pubmed.ncbi.nlm.nih.gov/35434595
https://pubmed.ncbi.nlm.nih.gov/35434595
Publikováno v:
Cancer Research. 81:304-304
Background Ovarian cancer (OC) is among the most commonly diagnosed cancers and combined with the low responses to therapeutics, it has the highest mortality among gynecological cancers. When diagnosed at stage III and stage IV, survival rates remain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f1dfc4222b2f338793e9c62cbaa8259
https://doi.org/10.1158/1538-7445.am2021-304
https://doi.org/10.1158/1538-7445.am2021-304